"Redefining healthy aging through expert, comprehensive, compassionate care for people facing memory loss, dementia and related challenges. From assessment and treatment to research and advocacy, the Kawartha Centre improves the lives of patients, families, caregivers and communities."

During the past decade, Kawartha Centre - Redefining Healthy Aging conducted 21 clinical trials. In the 10-year time frame, 21 clinical trials started and 14 clinical trials were completed, i.e. on average, 66.7% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 10 clinical trials were completed. i.e. 125% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Kawartha Centre - Redefining Healthy Aging" #1 sponsor was "Hoffmann-La Roche" with 7 trials, followed by "AstraZeneca" with 3 trials sponsored, "Anavex Life Sciences Corp." with 2 trials sponsored, "Biogen" with 2 trials sponsored and "Eli Lilly and Company" with 2 trials sponsored. Other sponsors include 10 different institutions and companies that sponsored additional 17 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Kawartha Centre - Redefining Healthy Aging" #1 collaborator was "Eli Lilly and Company" with 4 trials as a collaborator, "Anavex Australia Pty Ltd." with 2 trials as a collaborator, "Anavex Germany GmbH" with 2 trials as a collaborator, "Pfizer" with 2 trials as a collaborator and "AbbVie" with 1 trials as a collaborator. Other collaborators include 13 different institutions and companies that were collaborators in the rest 23 trials.

According to Clinical.Site data, the most researched conditions in "Kawartha Centre - Redefining Healthy Aging" are "Alzheimer's Disease" (15 trials), "Alzheimer Disease" (10 trials), "Dementia" (2 trials), "Early Alzheimer's Disease" (2 trials) and "Alzheimers Disease" (1 trials). Many other conditions were trialed in "Kawartha Centre - Redefining Healthy Aging" in a lesser frequency.

Most popular intervention types in "Kawartha Centre - Redefining Healthy Aging" are "Drug" (30 trials), "Other" (2 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (17 trials), "Crenezumab" (4 trials), "Gantenerumab" (4 trials), "Lanabecestat" (3 trials) and "Donanemab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Kawartha Centre - Redefining Healthy Aging" are 31 trials for "All" genders.

Currently, there are NaN active trials in "Kawartha Centre - Redefining Healthy Aging". undefined are not yet recruiting, 6 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 12 completed trials in Kawartha Centre - Redefining Healthy Aging, undefined suspended trials, and 9 terminated clinical trials to date.

Out of the total trials that were conducted in Kawartha Centre - Redefining Healthy Aging, 0 "Phase 1" clinical trials were conducted, 14 "Phase 2" clinical trials and 19 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".